A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6563-6574

  Chiuppesi, Flavia ^a   Vannucci, Laura ^a   De Luca, Anna ^a   Lai, Michele ^a   Matteoli, Barbara ^a   Freer, Giulia ^a   Ceccherini Nelli, Roberto Manservigi ^b   Maggi, Fabrizio ^a   Bendinelli, Mauro ^a   Pistello, Mauro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GLYCOPROTEIN B VACCINE; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CROSS PROTECTION; FEMALE; GENETIC VECTORS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNODEFICIENCY VIRUS, FELINE; MICE; MICE, INBRED C57BL; VACCINATION; VIRAL ENVELOPE PROTEINS;

ANIMALIA; FELINE IMMUNODEFICIENCY VIRUS; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS; SIMPLEXVIRUS;

EID: 84863992168     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00302-12     Document Type: Article

References (69)

1. Abu-Raddad LJ, et al. 2008. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 3:e2230.
2. Andrei G, et al. 2011. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 10: 379-389.
3. Arii J, et al. 2010. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 467:859-862.
4. Barraza RA, et al. 2009. Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates. Hum. Gene Ther. 20:191-200.
5. Belshe RB, et al. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43.
6. Bzik DJ, Debroy C, Fox BA, Pederson NE, Person S. 1986. The nucleotide sequence of the gB glycoprotein gene of HSV-2 and comparison with the corresponding gene of HSV-1. Virology 155:322-333.
7. Campadelli-Fiume G, et al. 2007. The multipartite system that mediates entry of herpes simplex virus into the cell. Rev. Med. Virol. 17:313-326.
8. Campan M, et al. 2011. Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiac MRI in a rat model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 300:H2238-H2250.
9. Caselli E, et al. 2001. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection. Intervirology 44:1-7.
10. Centers for Disease Control and Prevention. 2012. HIV, STD and TB prevention. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/std/Herpes/STDFact-Herpes.htm.
11. Cernik C, Gallina K, Brodell RT. 2008. The treatment of herpes simplex infections: an evidence-based review. Arch. Intern. Med. 168:1137-1144.
12. Chentoufi AA, et al. 2008. Asymptomatic human CD4_ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82:11792-11802.
13. Corey L, Handsfield H. 2000. Genital herpes and public health: addressing a global problem. JAMA 283:791-794.
14. Corey L, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
15. Coutant F, Frenkiel MDP, Charneau P. 2008. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3:e3973.
16. Coyle P, Desai A, Wyatt D, McCaughey C, O'Neill H. 1999 A comparison of virus isolation, indirect immunofluorescence and nested multiplex polymerase chain reaction for the diagnosis of primary and recurrent herpes simplex type 1 and type 2 infections. J. Virol. Methods 83:75- 82.
17. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. 2009. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines 8:1023-1035.
18. Domingo C, et al. 2003. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine 21:3565-3574.
19. Dropulic B. 2011. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum. Gene Ther. 22:649-657.
20. Elder JH, Lin YC, Fink E, Grant CK. 2010. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr. HIV Res. 8:73- 80.
21. Farley N, et al. 2010. Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy. Antivir. Res. 86:188-195.
22. Fleming D, McQuillan G, Johnson R. 1997. Herpes simplex virus type 2 in the United States, 1976-1994. N. Engl. J. Med. 337:1105.
23. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Ozaki A, Ueno H. 2005 The immunization protocol determines whether endogenous interferon-gamma suppresses the infiltration of eosinophils into the conjunctiva. Immunol. Lett. 100:189 -194.
24. Grinshpun A, et al. 2010. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector. Mol. Ther. 18:1592-1598.
25. Hanke T, Graham F, Rosenthal K, Johnson D. 1991. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J. Virol. 65:1177-1186.
26. Hu B, Tai A, Wang P. 2011. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol. Rev. 239:45- 61.
27. Johnston C, Koelle DM, Wald A. 2011. HSV-2: in pursuit of a vaccine. J. Clin. Invest. 121:4600-4609.
28. Kim SB, et al. 2009. Modulation of protective immunity against herpes simplex virus via mucosal genetic cotransfer of DNA vaccine with beta2-adrenergic agonist. Exp. Mol. Med. 41:812- 823.
29. Krawczyk A, et al. 2011. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J. Virol. 85:1793-1803.
30. Lee AJ, Ashkar AA. 2012. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development. Curr. Opin. Infect. Dis. 25:92-99.
31. Lopes L, Dewannieux MT, Takayuki Y, Collins MK. 2011. A lentiviral vector pseudotype suitable for vaccine development. J. Gene Med. 13:181- 187.
32. Manickan E, et al. 1995. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4_ Th1_ T cells. J. Virol. 69:4711- 4716.
33. Manservigi R, et al. 1988. Constitutive expression in human cells of herpes simplex virus type 1 glycoprotein B gene cloned in an episomal eukaryotic vector. Virology 167:284 -288.
34. McClements WL, Armstrong ME, Keys RD, Liu MA. 1996. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. U. S. A. 93:11414-11420.
35. Mueller SN, et al. 2003. The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8_ T cells. J. Virol. 77:2445-2451.
36. Muller WJ, et al. 2008. Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2. Arch. Virol. 153:1165-1169.
37. Negri D, et al. 2011. Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin. Biol. Ther. 11:739 -750.
38. Nikolic DS, Piguet V. 2010. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. J. Invest. Dermatol. 130:352-361.
39. Orr MT, Orgun NN, Wilson CB, Way SS. 2007. Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J. Immunol. 178:4731- 4735.
40. Palliser D, et al. 2006. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439:89 -94.
41. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. 2007. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex. Transm. Infect. 83:16 -22.
42. Pistello M, et al. 2006. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J. Virol. 80:8856-8868.
43. Pistello M, et al. 2007. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet. Vaccines Ther. 5:8.
44. Pouriayevali MH, Bamdad T, Parsania M, Sari RD. 2011. Full-length antigen priming enhances the CTL epitope-based DNA vaccine efficacy. Cell. Immunol. 268:4-8.
45. Ramachandran S, Davoli KA, Yee MB, Hendricks RL, Kinchington PR. 2010. Delaying the expression of herpes simplex virus type 1 glycoprotein B (gB) to a true late gene alters neurovirulence and inhibits the gB-CD8_ T-cell response in the trigeminal ganglion. J. Virol. 84:8811- 8820.
46. Reed L, Muench H. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 1938:493- 497.
47. Roizman B, Knipe DM, Whitley R. 2007. Herpes simplex viruses, p 2501-2602. In Knipe DM, et al. (ed), Fields virology, 5th ed. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
48. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. 2011. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23:377-382.
49. Russell MW, Mestecky J. 2002. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 4:667- 677.
50. Sandrin V, et al. 2002. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34_ cells derived from human and nonhuman primates. Blood 100:823- 832.
51. Schiffer JT, et al. 2010. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc. Natl. Acad. Sci. U. S. A. 107:18973-18978.
52. Sinn PL, Arias AC, Brogden KA, McCray PB, Jr. 2008. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J. Virol. 82:10684 -10692.
53. Smith JS, et al. 2002. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 94:1604 -1613.
54. Steinman RM. 2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30:1-22.
55. Suenaga T, et al. 2010. Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Proc. Natl. Acad. Sci. U. S. A. 107:866-871.
56. Tang VA, Rosenthal KL. 2010. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J. Reprod. Immunol. 87:39-44.
57. Taylor JM, et al. 2007. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2:19 -28.
58. Teepe AG, Allen LB, Wordinger RJ, Harris EF. 1990. Effect of the estrous cycle on susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2 (HSV-2). Antivir. Res. 14:227-235.
59. Tognon M, et al. 1985. Analysis of HSV isolated from patients with unilateral and bilateral herpetic keratitis. Int. Ophthalmol. 8:13-18.
60. Valori CF, Ning K, Wyles M, Azzouz M. 2008. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Curr. Gene Ther. 8:406-418.
61. Vannucci L, et al. 2010. Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer. Vet. Immunol. Immunopathol. 134:132-137.
62. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. 2009. Nonmuscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell. Biol. 10:778 -790.
63. Wald A. 2004. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 11:130A-137A.
64. Wang X, et al. 2011. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice. Virol. J. 8:232.
65. Wilson SS, Fakioglu E, Herold BC. 2009. Novel approaches in fighting herpes simplex virus infections. Expert Rev. Anti-Infect. Ther. 7:559 -568.
66. Xu F, et al. 2010. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years in United States, 2005-2008. MMWR Morb. Mortal. Wkly. Rep. 59:456-459.
67. Xu F, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964 -973.
68. Zhu J, et al. 2007. Virus-specific CD8_ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204:595- 603.
69. Zhou X, Berg L, Motal UM, Jondal M. 1992. In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. J. Immunol. Methods 153:193-200.